Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
PF Holdings Raises Pininfarina Offer to EUR 1.20 a Share

PF Holdings Raises Pininfarina Offer to EUR 1.20 a Share

BitgetBitget2026/11/05 19:29
  • PF Holdings raised its offer for Pininfarina to EUR 1.20 per ordinary share from EUR 1 on November 5, 2026.
  • Alfonso Prascina irrevocably committed to tender his entire holding of 7,886,000 ordinary shares, representing 10.02% of share capital.
  • The offer covers 13,700,787 ordinary shares not already held by PF Holdings, with maximum consideration rising to EUR 16.44 million.
  • PF Holdings already owns 82.59% of share capital; the acceptance period began October 26, 2026.
  • The revised price represents a 44% premium to the EUR 0.833 closing official share price on September 15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pininfarina S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 0205-43-2026_TELEBORSA.pdf), on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss